Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update
February 28, 2022 17:29 ET
|
SPK Acquisition Corp.
NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and...
Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.
February 14, 2022 09:00 ET
|
SPK Acquisition Corp.
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a...
SPK Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about July 23, 2021
July 23, 2021 06:00 ET
|
SPK Acquisition Corp.
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. ("the Company" or "SPK") (NASDAQ: SPKAU), a blank check company formed for the purpose of entering into a merger, share exchange,...
SPK Acquisition Corp. Announces Pricing of $50 Million Initial Public Offering
June 07, 2021 21:55 ET
|
SPK Acquisition Corp.
NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. (NASDAQ: SPKAU, the "Company") announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The...